Graham Cooper

Graham K.
Cooper is currently an Independent Director at Beam Therapeutics, Inc. since 2019 and Chief Financial Officer at Tavo Biotherapeutics, Inc. Former positions include Executive Chairman at Applied Molecular Transport, Inc. from 2022 to 2023, Chairman at Kezar Life Sciences, Inc. from 2022 to 2026, Director-Health Care Investment Banking at Deutsche Bank Securities, Inc. from 1997 to 2006, Independent Director at Celladon Corp.
from 2013 to 2016, Director at Bioniz Therapeutics, Inc., Independent Director at Unity Biotechnology, Inc. from 2017 to 2022, Chief Financial Officer & EVP-Business Development at Geron Corp.
in 2012, Chief Financial Officer, Treasurer & Senior VP at Orexigen Therapeutics, Inc. in 2011, CFO, CAO, Head-Investor & Media Relations at Receptos LLC from 2014 to 2015, Accountant at Deloitte & Touche LLP from 1992 to 1995, and Chief Operating, Financial & Accounting Officer at Assembly Biosciences, Inc. from 2018 to 2019.
Education includes undergraduate studies at the University of California, Berkeley and an MBA from Stanford Graduate School of Business.